Hydar's sales leadership enables Kent Imaging to further scale and grow.
CALGARY, Nov. 1, 2017 /CNW/ - Kent Imaging Inc. a leading innovator in multispectral oxygenation imaging, today announced Jeff Hydar as the new Vice President of Sales, USA. Jeff Hydar is an award winning strategic sales executive who has run successful teams throughout the United States. Hydar's experience guiding sales teams and his motivational leadership style will propel Kent's product sales in the wound and surgical care market.
"With Kent's recent FDA clearance of the KD203, we have a significant opportunity to simplify the way physicians and surgeons assess, care for, and monitor acute and chronic wounds or surgically reconstructed tissue." said Jeff Hydar. "Multispectral imaging is enabling a new generation of tools that use tissue oxygenation measurements to assess tissue viability. I'm very excited to help introduce this new technology into the market."
"Jeff brings over twenty years of pharmaceutical and medical device sales and leadership experience to Kent. His exceptional background and relationships in plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties are strong additions to the Kent team." said Pierre Lemire, CEO of Kent Imaging.
Hydar's prior experience with Johnson & Johnson, LifeCell (Acelity), and Medline has been focused on launching various new medical technologies and devices.
About Kent Imaging Inc.
Kent Imaging, a leading innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve health care. Headquartered in Calgary, Canada, Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally.
Kent's KD203 is U.S. Food and Drug Administration 510(k) cleared, and Health Canada licensed. The device is available for sale in the United States and Canada. Improving on Kent's previous KC103, the handheld Kent KD203 is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent's multispectral imaging technology displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes.
SOURCE Kent Imaging
For further information: Kent Imaging Inc., www.kentimaging.com, Vonda-Lee Sharun - Marketing Manager, firstname.lastname@example.org